Assessment of Quality of Life, Disease Activity and Productivity Loss of Patients with ulcerative colitis in Poland

• Autorzy: Paweł Kawalec , Ewa Stawowczyk , Malgorzata Mossakowska
• Języki publikacji: EN

Abstrakty

EN

Purpose: The aim of the study was to assess the relationship between the disease activity and both indirect costs and health-related quality of life among ulcerative colitis (UC) patients in Poland. Methods: A questionnaire-based, self-report survey was conducted using th (P-SCCAI) to assess disease activity, and the Work Productivity and Activity Impairment Questionnaire (WPAI) to assess productivity loss. The quality of life was presented as utility calculated using the EQ-5D-3L questionnaire. Additionally, the reduction of usual activities, other than paid work and the need of assistance were assessed. Indirect costs were assessed with the Human Capital Approach and were expressed in euros (€). Correlations were presented using the Spearman's coefficient, the between-group difference was assessed with Mann-Whitney U-test and Pearson c2 test. Results: 305 full questionnaires were collected. Indirect cost due to absenteeism and presenteeism per year per working patient with disease in remission was €2,559 (95%CI:1,283-3,835) and due to informal care was €10.38 (95%CI:0-31.20). The corresponding values for patients with active disease were €5,605 (95%CI:4,744-6,466) and €645.36 (95%CI:333.77-956.96). The between-group differences in above values was statistically significant (p<0.05). The difference in utility values between patients with disease in remission (0.934, 95%CI:0.919-0.949) and patients with active disease (0.826, 95% CI:0.807-0.845) was statistically significant. Conclusions: The statistically significant difference was identified in productivity loss and health related quality of life among patients with active disease and patients with disease in remission. The significant difference was also observed in the average reduction of usual activities and the need for assistance in performing usual activities. (original abstract)

Słowa kluczowe

EN

Quality of life; Life quality assessment; Illness; Chronic diseases; Spearman's rank correlation coefficient; Mann-Whitney test

PL

Jakość życia; Ocena jakości życia; Choroby; Choroby przewlekłe; Współczynnik korelacji rang Spearmana; Test Mann-Whitney

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2016
• Numer: nr 2
• Strony: 48--56

Twórcy

autor

Paweł Kawalec

• Collegium Medicum Jagiellonian University, Cracow, Poland; HTACenter, Cracow, Poland

autor

Ewa Stawowczyk

• StatSoft Polska Sp. z o.o.

autor

Malgorzata Mossakowska

• Polish Association Supporting People with Inflammatory Bowel Disease

Bibliografia

• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.
• Feagan BG, Reinisch W, Rutgeerts P, et al. The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients. Am J Gastroenterol 2007; 102: 794-802.
• Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380: 1606-19.
• Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21: 21-46.
• Krol M, Brouwer W. How to Estimate Productivity Costs in Economic Evaluations. PharmacoEconomics 2014; 32: 335-44.
• Evertsz' FB, Nieuwkerk PT, Stokkers PCF, et al. The Patient Simple Clinical Colitis Activity Index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: A comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis 2013; 7: 890-900.
• Krol M, Brouwer W. How to Estimate Productivity Costs in Economic Evaluations. PharmacoEconomics 2014; 32: 335-44.
• Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach JJ. Valuation of EQ-5D health states in Poland: first TTO based social value set in Central and Eastern Europe. Value Health. 2010; 13:289-97.
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4: 353-65.
• Central Statistical Office of Poland, http://stat.gov.pl/ en/ Last Access: January 2016.
• Havik K, Mc Morrow K, Orlandi F, et al. The production function methodology for calculating potential growth rates and output gaps. Economic Papers 535, November 2014, http://ec.europa.eu/economy_finance/ publications/economic_paper/2014/pdf/ecp535_en.pdf.
• Casellas F, Alcalá MJ, Prieto L, Miró JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004.
• Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2014 Jul;8(7):598-606.
• Mandel MD, Bálint A, Lovász BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014 May;15 Suppl 1:S121-8.
• Taleban S, Stewart KO, Li DK, et al. Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci. 2016;61(9):2627-35.
• Kawalec P, Malinowski KP. Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015; 15: 253-66.
• Cohen R, Rizzo J, Yang M, et al. Direct and Indirect Utilization and Costs Associated with Ulcerative Colitis. Am J Gastroenterol 2012; 107: S608-95.

Identyfikatory

DOI

10.7365/JHPOR.2016.2.5